Silent information regulator 2 homolog 1 counters cerebral hypoperfusion injury by deacetylating endothelial nitric oxide synthase

Stroke

Volumn 45, Issue 11, 2014, Pages 3403-3411

  Hattori, Yorito ^a,b   Okamoto, Yoko ^b   Maki, Takakuni ^c   Yamamoto, Yumi ^b   Oishi, Naoya ^a   Yamahara, Kenichi ^b   Nagatsuka, Kazuyuki ^b   Takahashi, Ryosuke ^a,d   Kalaria, Raj N ^e   Fukuyama, Hidenao ^a   Kinoshita, Makoto ^d,f   Ihara, Masafumi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f NAGOYA UNIVERSITY   (Japan)

Author keywords

Carotid artery stenosis; Cerebral ischemia; Dementia; Endothelial nitric oxide synthase

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; SILENT INFORMATION REGULATOR PROTEIN 2; NOS3 PROTEIN, MOUSE; SIRT1 PROTEIN, MOUSE; SIRTUIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN HOMOGENATE; BRAIN INJURY; BRAIN PROTECTION; CAROTID ARTERY OBSTRUCTION; CEREBRAL HYPOPERFUSION INJURY; COMMON CAROTID ARTERY; GENE OVEREXPRESSION; HISTOLOGY; IMMUNOPRECIPITATION; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRION; PRIORITY JOURNAL; PROMOTER REGION; VASODILATATION; WORKING MEMORY; ACETYLATION; ANIMAL; BIOSYNTHESIS; BRAIN CIRCULATION; BRAIN INJURIES; C57BL MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ACETYLATION; ANIMALS; BRAIN INJURIES; CEREBROVASCULAR CIRCULATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE III; SIRTUIN 1;

EID: 84922480609     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006265     Document Type: Article

References (40)

1. Klar AJ, Fogel S, Macleod K. MAR1-A regulator of the HMa and HMalpha loci in Saccharomyces cerevisiae. Genetics. 1979;93:37-50.
2. Duan W. Sirtuins: from metabolic regulation to brain aging. Front Aging Neurosci. 2013;5:36.
3. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403:795-800.
4. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191-196.
5. Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature. 2001;410:227-230.
6. Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A. 2004;101:15998-16003.
7. Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, et al. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 2013;18:416-430.
8. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses betaamyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010;142:320-332.
9. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010;67:953-966.
10. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23:2369-2380.
11. Wang R, Li JJ, Diao S, Kwak YD, Liu L, Zhi L, et al. Metabolic stress modulates Alzheimer's β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons. Cell Metab. 2013;17:685-694.
12. Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, et al. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem. 2009;284:21379-21385.
13. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007;26:3169-3179.
14. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol. 2011;95:373-395.
15. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience. 2009;159:993-1002.
16. Hernández-Jiménez M, Hurtado O, Cuartero MI, Ballesteros I, Moraga A, Pradillo JM, et al. Silent information regulator 1 protects the brain against cerebral ischemic damage. Stroke. 2013;44:2333-2337.
17. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 2013;136(pt 9):2697-2706.
18. Kalaria RN, Ihara M. Dementia: vascular and neurodegenerative pathways-will they meet? Nat Rev Neurol. 2013;9:487-488.
19. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke. 2004;35:2598-2603.
20. Shibata M, Yamasaki N, Miyakawa T, Kalaria RN, Fujita Y, Ohtani R, et al. Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke. 2007;38:2826-2832.
21. Watanabe S, Ageta-Ishihara N, Nagatsu S, Takao K, Komine O, Endo F, et al. SIRT1 overexpression ameliorates a mouse model of SOD1-linked amyotrophic lateral sclerosis via HSF1/HSP70 chaperone system. Mol Brain. 2014;7:62.
22. Dvir-Ginzberg M, Gagarina V, Lee EJ, Booth R, Gabay O, Hall DJ. Tumor necrosis factor α-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. Arthritis Rheum. 2011;63:2363-2373.
23. Simák J, Holada K, D'Agnillo F, Janota J, Vostal JG. Cellular prion protein is expressed on endothelial cells and is released during apoptosis on membrane microparticles found in human plasma. Transfusion. 2002;42:334-342.
24. Starke R, Drummond O, MacGregor I, Biggerstaff J, Gale R, Camilleri R, et al. The expression of prion protein by endothelial cells: a source of the plasma form of prion protein? Br J Haematol. 2002;119:863-873.
25. Pflanzner T, Petsch B, André-Dohmen B, Mu¨ller-Schiffmann A, Tschickardt S, Weggen S, et al. Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:628-632.
26. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2007;104:14855-14860.
27. Osuka K, Watanabe Y, Usuda N, Nakazawa A, Tokuda M, Yoshida J. Modification of endothelial NO synthase through protein phosphorylation after forebrain cerebral ischemia/reperfusion. Stroke. 2004;35:2582-2586.
28. Arunachalam G, Yao H, Sundar IK, Caito S, Rahman I. SIRT1 regulates oxidant-and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem Biophys Res Commun. 2010;393:66-72.
29. Fujita Y, Ihara M, Ushiki T, Hirai H, Kizaka-Kondoh S, Hiraoka M, et al. Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke. 2010;41:2938-2943.
30. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 2002;33:1152-1162.
31. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S115-S123.
32. Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev. 2010;68(suppl 2):S74-S87.
33. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012;322:141-147.
34. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813-817.
35. Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO. Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol. 2013;39:593-611.
36. Arbel-Ornath M, Hudry E, Eikermann-Haerter K, Hou S, Gregory JL, Zhao L, et al. Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer's disease mouse models. Acta Neuropathol. 2013;126:353-364.
37. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330:1774.
38. Hawkes CA, Härtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, et al. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 2011;121:431-443.
39. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JA, Carare RO. Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One. 2012;7:e41636.
40. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241-249.